



Health Alert Network Message 22-03: Therapeutics for Outpatient Use in the Prevention or Treatment of COVID-19

Origination Date:

January 14, 2022

Revision Dates (List All Revision Dates):

Therapeutics for Outpatient Use in the Prevention or Treatment of COVID-19

The U.S. Food and Drug Administration have issued new Emergency Use Authorizations for therapeutics that may be used in the prevention or treatment of COVID-19 in specific at-risk populations.

Some of these therapeutics are in limited supply but availability is expected to increase in the coming months.

For more information on the use of these therapeutics, including contraindications and prescribing information, please see the attached CDC Health Advisory "Using Therapeutics to Prevent and Treat COVID-19"

Pfizer's Paxlovid (ritonavir-boosted nirmatrelvir) and Merck's molnupirivir in particular have prescribing limitations and drug interactions that clinicians must be familiar with prior to counseling and prescribing for patients. Clinicians should closely review the respective Fact Sheets for Health Care Providers.

Paxlovid Fact Sheet for Healthcare Providers: <https://www.fda.gov/media/155050/download>
molnupirivir Fact Sheet for Healthcare Providers: <https://www.fda.gov/media/155054/download>

Providers can utilize the HHS COVID-19 Therapeutics Locator to identify available supply of these products: <https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>. Supply is expected to increase over the coming weeks.